Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Sep
01
Today In Oncology
Biomarker Guides Treatment Sequencing Predicts Outcomes in BRAF-Mutated Metastatic Melanoma
High-Dose Vitamin D3 Does Not Improve PFS in Metastatic Colorectal Cancer
Additional Safety Analysis of DESTINY-Breast05: What Did It Show?
FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo